DDriver

An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deﬁciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)

Open

Trial drug

Tuvusertib, Lartesertib, Niraparib

Grade

High grade

Prior lines

1, 2

Biomarkers

BRCA1, HRD, BRCA2

Histology

Serous, Endometrioid

Platin

Platinum sensitive

Phase

Treatment

This study consists of two different treatment options:

Tuvusertib + Niraparib
Tuvusertib + Lartesertib

You will be randomly allocated to one of both treatment groups.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.